Skip to main content
Erschienen in: Digestive Diseases and Sciences 6/2010

01.06.2010 | Original Article

Incidence and Risk of Intestinal and Extra-intestinal Complications in Medicaid Patients with Inflammatory Bowel Disease: A 5-Year Population-Based Study

verfasst von: Gaurav Arora, Gurkirpal Singh, Shweta Vadhavkar, Shamita B. Shah, Ajitha Mannalithara, Alka Mithal, George Triadafilopoulos

Erschienen in: Digestive Diseases and Sciences | Ausgabe 6/2010

Einloggen, um Zugang zu erhalten

Abstract

Background and Aim

Intestinal and extra-intestinal complications are associated with inflammatory bowel disease (IBD) but their exact incidence is not well known. In order to improve our understanding of their incidence and impact, we assessed the complications associated with ulcerative colitis (UC) and Crohn’s disease (CD) in a population-based study in Medicaid patients.

Methods

We utilized a retrospective cohort design and identified cases of UC and CD using Medi-Cal, the Medicaid program for the State of California. The disease cohort was age- and gender-matched to four controls each and the intestinal and extra-intestinal complications of CD and UC (analyzed separately) were studied over a period of 5 years following the initial diagnosis.

Results

For UC, the total number of intestinal complications, per 100 cases, was 92 observed compared to 21 expected; the total number of extra-intestinal complications was 42 observed compared to 30 expected. For CD, the number of intestinal complications was 81 observed compared to 20 expected and for extra-intestinal complications, 37 observed compared to 26 expected (all p < 0.001). For both UC and CD, bleeding was the most frequently seen intestinal complication, while the most common extra-intestinal complication was osteoporosis.

Conclusions

IBD is associated with several intestinal and extra-intestinal complications of variable incidence and risk. Success of therapeutic regimens should be measured by decreases in incidence, risks, and costs of these complications, in addition to the usual impact on disease activity.
Literatur
2.
Zurück zum Zitat National Institute of Diabetes and Digestive and Kidney Diseases. Digestive Diseases in the United States: Epidemiology and Impact. Washington, DC: US Government Printing Office. In; 1994 NIH publication 94–1447. National Institute of Diabetes and Digestive and Kidney Diseases. Digestive Diseases in the United States: Epidemiology and Impact. Washington, DC: US Government Printing Office. In; 1994 NIH publication 94–1447.
4.
Zurück zum Zitat Farmer RG, Hawk WA, Turnbull RB Jr. Clinical patterns in Crohn’s disease: a statistical study of 615 cases. Gastroenterology. 1975;68:627–635.PubMed Farmer RG, Hawk WA, Turnbull RB Jr. Clinical patterns in Crohn’s disease: a statistical study of 615 cases. Gastroenterology. 1975;68:627–635.PubMed
5.
Zurück zum Zitat Greenstein AJ, Janowitz HD, Sachar DB. The extra-intestinal complications of Crohn’s disease and ulcerative colitis: a study of 700 patients. Medicine (Baltimore). 1976;55:401–412.CrossRef Greenstein AJ, Janowitz HD, Sachar DB. The extra-intestinal complications of Crohn’s disease and ulcerative colitis: a study of 700 patients. Medicine (Baltimore). 1976;55:401–412.CrossRef
6.
Zurück zum Zitat Monsen U, Sorstad J, Hellers G, Johansson C. Extracolonic diagnoses in ulcerative colitis: an epidemiological study. Am J Gastroenterol. 1990;85:711–716.PubMed Monsen U, Sorstad J, Hellers G, Johansson C. Extracolonic diagnoses in ulcerative colitis: an epidemiological study. Am J Gastroenterol. 1990;85:711–716.PubMed
7.
Zurück zum Zitat Rankin GB, Watts HD, Melnyk CS, Kelley ML Jr. National Cooperative Crohn’s Disease study: extraintestinal manifestations and perianal complications. Gastroenterology. 1979;77:914–920.PubMed Rankin GB, Watts HD, Melnyk CS, Kelley ML Jr. National Cooperative Crohn’s Disease study: extraintestinal manifestations and perianal complications. Gastroenterology. 1979;77:914–920.PubMed
8.
Zurück zum Zitat Veloso FT, Carvalho J, Magro F. Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients. J Clin Gastroenterol. 1996;23:29–34.CrossRefPubMed Veloso FT, Carvalho J, Magro F. Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients. J Clin Gastroenterol. 1996;23:29–34.CrossRefPubMed
12.
Zurück zum Zitat Parc R, Roger V, Penna C. Management of hemorrhage. In: Michelassi F, Milsom JW, eds. Operative strategies in inflammatory bowel disease. New York: Springer; 1999:229–233. Parc R, Roger V, Penna C. Management of hemorrhage. In: Michelassi F, Milsom JW, eds. Operative strategies in inflammatory bowel disease. New York: Springer; 1999:229–233.
13.
Zurück zum Zitat Robert JR, Sachar DB, Greenstein AJ. Severe gastrointestinal hemorrhage in Crohn’s disease. Ann Surg. 1991;213:207–211.CrossRefPubMed Robert JR, Sachar DB, Greenstein AJ. Severe gastrointestinal hemorrhage in Crohn’s disease. Ann Surg. 1991;213:207–211.CrossRefPubMed
14.
Zurück zum Zitat Robert JH, Sachar DB, Aufses AH Jr, Greenstein AJ. Management of severe hemorrhage in ulcerative colitis. Am J Surg. 1990;159:550–555.CrossRefPubMed Robert JH, Sachar DB, Aufses AH Jr, Greenstein AJ. Management of severe hemorrhage in ulcerative colitis. Am J Surg. 1990;159:550–555.CrossRefPubMed
15.
Zurück zum Zitat Jahnsen J, Falch JA, Mowinckel P, Aadland E. Bone mineral density in patients with inflammatory bowel disease: a population-based prospective two-year follow-up study. Scand J Gastroenterol. 2004;39:145–153.CrossRefPubMed Jahnsen J, Falch JA, Mowinckel P, Aadland E. Bone mineral density in patients with inflammatory bowel disease: a population-based prospective two-year follow-up study. Scand J Gastroenterol. 2004;39:145–153.CrossRefPubMed
16.
Zurück zum Zitat Schulte C, Dignass AU, Mann K, Goebell H. Reduced bone mineral density and unbalanced bone metabolism in patients with inflammatory bowel disease. Inflamm Bowel Dis. 1998;4:268–275.CrossRefPubMed Schulte C, Dignass AU, Mann K, Goebell H. Reduced bone mineral density and unbalanced bone metabolism in patients with inflammatory bowel disease. Inflamm Bowel Dis. 1998;4:268–275.CrossRefPubMed
17.
Zurück zum Zitat Jahnsen J, Falch JA, Aadland E, Mowinckel P. Bone mineral density is reduced in patients with Crohn’s disease but not in patients with ulcerative colitis: a population-based study. Gut. 1997;40:313–319.PubMed Jahnsen J, Falch JA, Aadland E, Mowinckel P. Bone mineral density is reduced in patients with Crohn’s disease but not in patients with ulcerative colitis: a population-based study. Gut. 1997;40:313–319.PubMed
18.
Zurück zum Zitat Silvennoinen JA, Karttunen TJ, Niemela SE, Manelius JJ, Lehtola JK. A controlled study of bone mineral density in patients with inflammatory bowel disease. Gut. 1995;37:71–76.CrossRefPubMed Silvennoinen JA, Karttunen TJ, Niemela SE, Manelius JJ, Lehtola JK. A controlled study of bone mineral density in patients with inflammatory bowel disease. Gut. 1995;37:71–76.CrossRefPubMed
19.
Zurück zum Zitat Bargiggia S, Maconi G, Elli M, et al. Sonographic prevalence of liver steatosis and biliary tract stones in patients with inflammatory bowel disease: study of 511 subjects at a single center. J Clin Gastroenterol. 2003;36:417–420.CrossRefPubMed Bargiggia S, Maconi G, Elli M, et al. Sonographic prevalence of liver steatosis and biliary tract stones in patients with inflammatory bowel disease: study of 511 subjects at a single center. J Clin Gastroenterol. 2003;36:417–420.CrossRefPubMed
20.
Zurück zum Zitat Kratzer W, Haenle MM, Mason RA, von Tirpitz C, Kaechele V. Prevalence of cholelithiasis in patients with chronic inflammatory bowel disease. World J Gastroenterol. 2005;11:6170–6175.PubMed Kratzer W, Haenle MM, Mason RA, von Tirpitz C, Kaechele V. Prevalence of cholelithiasis in patients with chronic inflammatory bowel disease. World J Gastroenterol. 2005;11:6170–6175.PubMed
21.
Zurück zum Zitat Fraquelli M, Losco A, Visentin S, et al. Gallstone disease and related risk factors in patients with Crohn's disease: analysis of 330 consecutive cases. Arch Intern Med. 2001;161:2201–2204.CrossRefPubMed Fraquelli M, Losco A, Visentin S, et al. Gallstone disease and related risk factors in patients with Crohn's disease: analysis of 330 consecutive cases. Arch Intern Med. 2001;161:2201–2204.CrossRefPubMed
22.
Zurück zum Zitat Orchard TR, Wordsworth BP, Jewell DP. Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut. 1998;42:387–391.PubMedCrossRef Orchard TR, Wordsworth BP, Jewell DP. Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut. 1998;42:387–391.PubMedCrossRef
23.
Zurück zum Zitat Salvarani C, Vlachonikolis IG, van der Heijde DM, et al. Musculoskeletal manifestations in a population-based cohort of inflammatory bowel disease patients. Scand J Gastroenterol. 2001;36:1307–1313.CrossRefPubMed Salvarani C, Vlachonikolis IG, van der Heijde DM, et al. Musculoskeletal manifestations in a population-based cohort of inflammatory bowel disease patients. Scand J Gastroenterol. 2001;36:1307–1313.CrossRefPubMed
24.
Zurück zum Zitat Bernstein CN, Blanchard JF, Rawsthorne P, Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol. 2001;96:1116–1122.CrossRefPubMed Bernstein CN, Blanchard JF, Rawsthorne P, Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol. 2001;96:1116–1122.CrossRefPubMed
25.
Zurück zum Zitat Jess T, Gamborg M, Matzen P, Munkholm P, Sorensen TI. Increased risk of intestinal cancer in Crohn’s disease: a meta-analysis of population-based cohort studies. Am J Gastroenterol. 2005;100:2724–2729.CrossRefPubMed Jess T, Gamborg M, Matzen P, Munkholm P, Sorensen TI. Increased risk of intestinal cancer in Crohn’s disease: a meta-analysis of population-based cohort studies. Am J Gastroenterol. 2005;100:2724–2729.CrossRefPubMed
26.
Zurück zum Zitat Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48:526–535.CrossRefPubMed Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48:526–535.CrossRefPubMed
27.
Zurück zum Zitat Kappelman MD, Rifas-Shiman SL, Kleinman K, et al. The prevalence and geographic distribution of Crohn’s disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol. 2007;5:1424–1429.CrossRefPubMed Kappelman MD, Rifas-Shiman SL, Kleinman K, et al. The prevalence and geographic distribution of Crohn’s disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol. 2007;5:1424–1429.CrossRefPubMed
Metadaten
Titel
Incidence and Risk of Intestinal and Extra-intestinal Complications in Medicaid Patients with Inflammatory Bowel Disease: A 5-Year Population-Based Study
verfasst von
Gaurav Arora
Gurkirpal Singh
Shweta Vadhavkar
Shamita B. Shah
Ajitha Mannalithara
Alka Mithal
George Triadafilopoulos
Publikationsdatum
01.06.2010
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 6/2010
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-010-1236-z

Weitere Artikel der Ausgabe 6/2010

Digestive Diseases and Sciences 6/2010 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Neuer Myosin-Inhibitor bei hypertropher Kardiomyopathie von Nutzen

17.05.2024 Kardiomyopathie Nachrichten

Mit Aficamten hat ein zweiter kardialer Myosin-Inhibitor seinen therapeutischen Nutzen bei symptomatischen Patienten mit obstruktiver hypertropher Kardiomyopathie (HCM) in einer randomisierten Phase-III-Studie klar unter Beweis gestellt.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.